Business
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced t
About this update from Lb Pharmaceuticals Inc
[{"type":"image","alt":"LB Pharmaceuticals Inc","displaySize":"","headline":null,"caption":"LB Pharmaceuticals Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":136,"url":"https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WMouKAmWk2ehxmDB5xPULw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MA--/https://media.zenfs.com/en/globenewswire.com/2840fbb85165e0ffde8f4da0174483e2","width":300,"height":136}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S.","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":172,"olType":false},{"type":"text","content":"NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizophrenia: A Phase 2 Randomized Clinical Trial.” LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders.","length":814,"tagName":"p"},{"type":"text","content":"“We are pleased to publish the positive results from the Phase 2 NOVA-1 trial in this prestigious, peer-reviewed journal, which we believe underscores the potential for LB-102, if approved, to become an important new treatment option for patients with schizophrenia,” commented Anna Eramo, MD, Chief Medical Officer of LB Pharmaceuticals. “Based on LB-102’s unique mechanism and these compelling clinical results, we have advanced LB-102 into the pivotal Phase 3 NOVA-2 trial for patients with schizophrenia the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression and plan t...